Greenwich LifeSciences, Inc. announced progress in its Phase III clinical ... superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

Other outcomes at return to sport included the Askling H-test, hamstring strength, clinical examination and readiness questions ... We predefined our sample size calculation and based it on previously ...

Correspondence to Dr Thomas Bandholm, Dept of Clinical Research ... reason you had to add or remove outcomes during the trial, we recommend you report this transparently, with reasons. This sample ...

STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...

sample size, and cost. 12 The goal of developing treatments faster while exposing fewer patients to the risks and burdens of clinical trials is laudable; however, the use of surrogates introduces ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

Now, the first clinical trial – although relatively small and ... among a subsection of participants who smoked. Though the sample size was small – just 13 of the 48 participants reported ...

Eligibility criteria included a primary tumor with a clinical stage of cT1 cN+, cT2–4a cN+, or cT2–4a cN0 disease, in which T indicates the size ... trial with 90% power to show the ...